Everything below concerns aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
== Passport power == The Henley Passport Index 2019 measures how many nations a given passport can enter without a visa. It ranks 190 nations on the "strength" of its passport. Thailand was ranked 68 of 190 countries (1=strong passport; 190=weak passport). A Thai passport can gain entry to 75 nations visa free. Other ASEAN nations ranked were: Singapore, 2/189 countries visa-free; Malaysia, 12/179; Brunei, 21/165; Indonesia, 72/71; Philippines, 74/66; Cambodia, 84/54; Laos, 86/52; Vietnam, 87/51; Myanmar, 90/48. Arton Capital's Passport Index 2017 ranks 193 member nations of the UN, as well as six territories, a total of 199 passport-issuing entities, on the number of countries a given passport can enter either visa-free (VF) or with a visa on arrival (VOA). Thailand ranked 107th of 199 nations in the number of VF/VOA countries granting its citizens visa-less entry (1=most passport power; 199=least passport power). Other ASEAN nations ranked were Singapore, 3; Malaysia, 19; Brunei, 49; Philippines, 127; Indonesia, 137; Cambodia, 154; Vietnam, 159; Laos, 169; and Myanmar, 180. The Passport Index also ranks countries by the number of countries to which they extend VF or VOA visas, a "Welcoming Index". Thailand ranked 62nd of 104 nations (due to numerous ties) (1=most countries granted VF or VOA entry; 104=fewest countries granted VF or VOA entry). Other ASEAN nations ranked were Cambodia, 1; Laos, 15; Indonesia, 16; Malaysia, 17; Singapore, 18; Philippines, 19; Brunei, 70; Vietnam, 83; Myanmar, 96.
== Ethical, legal and social implications == Genetic information provides a unique type of knowledge about an individual and his/her family, fundamentally different from a typically laboratory test that provides a "snapshot" of an individual's health status. The unique status of genetic information and inherited disease has a number of ramifications with regard to ethical, legal, and societal concerns. On 19 March 2015, scientists urged a worldwide ban on clinical use of methods, particularly the use of CRISPR and zinc finger, to edit the human genome in a way that can be inherited. In April 2015 and April 2016, Chinese researchers reported results of basic research to edit the DNA of non-viable human embryos using CRISPR. In February 2016, British scientists were given permission by regulators to genetically modify human embryos by using CRISPR and related techniques on condition that the embryos were destroyed within seven days. In June 2016 the Dutch government was reported to be planning to follow suit with similar regulations which would specify a 14-day limit.
As with any other organic compound, it is prudent to characterize synthetic oligonucleotides upon their preparation. In more complex cases (research and large scale syntheses) oligonucleotides are characterized after their deprotection and after purification. Although the ultimate approach to the characterization is sequencing, a relatively inexpensive and routine procedure, the considerations of the cost reduction preclude its use in routine manufacturing of oligonucleotides. In day-by-day practice, it is sufficient to obtain the molecular mass of an oligonucleotide by recording its mass spectrum. Two methods are currently widely used for characterization of oligonucleotides: electrospray mass spectrometry (ESI MS) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). To obtain informative spectra, it is very important to exchange all metal ions that might be present in the sample for ammonium or trialkylammonium [e.c. triethylammonium, (C2H5)3NH+] ions prior to submitting a sample to the analysis by either of the methods.
== Preparation == To make a gelatine dessert, gelatine is dissolved in hot liquid with the desired flavours and other additives. These latter ingredients usually include sugar, fruit juice, or sugar substitutes; they may be added and varied during preparation, or pre-mixed with the gelatine in a commercial product which mainly requires the addition of hot water. In addition to sweeteners, the prepared commercial blends generally contain flavouring agents and other additives, such as adipic acid, fumaric acid, sodium citrate, and artificial flavourings and food colours. Because the collagen is processed extensively, the final product is not categorised as a meat or animal product by the United States federal government.
Sources: en.wikipedia.org
In cosmetic applications, botulinum toxin is considered relatively safe and effective for reduction of facial wrinkles, especially in the uppermost third of the face. Commercial forms are marketed under the brand names Botox Cosmetic/Vistabel from Allergan, Dysport/Azzalure from Galderma and Ipsen, Xeomin/Bocouture from Merz, Jeuveau/Nuceiva from Evolus, manufactured by Daewoong in South Korea. The effects of botulinum toxin injections for glabellar lines ("11's lines" between the eyes) typically last two to four months and in some cases, product-dependent, with some patients experiencing a longer duration of effect of up to six months or longer. Injection of botulinum toxin into the muscles under facial wrinkles causes relaxation of those muscles, resulting in the smoothing of the overlying skin. Smoothing of wrinkles is usually visible three to five days after injection, with maximum effect typically a week following injection. Muscles can be treated repeatedly to maintain the smoothed appearance. DaxibotulinumtoxinA (Daxxify) was approved for medical use in the United States in September 2022. It is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines. DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. The FDA approved daxibotulinumtoxinA based on evidence from two clinical trials (Studies GL-1 and GL-2), of 609 adults with moderate to severe glabellar lines. The trials were conducted at 30 sites in the United States and Canada.
In Indonesia, soy sauce is known as kecap (old spelling: ketjap), which is a catch-all term for fermented sauces, and cognate to the English word "ketchup". The most popular type of soy sauce in Indonesian cuisine is kecap manis or sweet soy sauce. The term kecap is also used to describe other condiments and sauces of a similar appearance, such as kecap ikan (fish sauce) and kecap Inggris (worcestershire sauce; lit. "English sauce" or "England sauce"). Three common varieties of soy-based kecap exist in Indonesian cuisine, used either as ingredients or condiments:
== External links == LAL Update Depyrogenation LAL Update FDA Office of Regulatory Affairs: Inspection Technical Guide, Bacterial Endotoxins/Pyrogens Textbook of Bacteriology Horseshoe Crab Medical Uses A Practical Approach to Depyrogenation Studies Using Bacterial Endotoxin
=== VFL Women's team === Essendon has fielded a team in the VFL Women's (VFLW) competition since the 2018 season. The league is the highest-grade competition for female footballers in Victoria and one of three second-tier female competitions underneath the national AFL Women's.
=== B cells === TGF-β1 has similar effects on B cells that also vary according to the differentiation state of the cell. It inhibits proliferation, stimulates apoptosis of B cells, and controls the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells.
Sources: en.wikipedia.org
=== Freshness and gas indicators === Freshness indicators respond to chemical or biological changes associated with product deterioration. They may react to pH changes, volatile amines, carbon dioxide, oxygen, hydrogen sulphide, humidity, or microbial metabolites. Gas indicators can show leakage, loss of the intended package atmosphere, or the presence or absence of a target gas. Biosensors combine a biological recognition element with a transducer that converts a reaction into a measurable signal. Freshness indicators do not replace microbiological testing or required date labelling. The indicator must be designed for the specific product, spoilage pathway, and storage environment.
In two-dimensional structures like graphene, thermal and quantum fluctuations cause relative displacement, with fluctuations growing logarithmically with structure size as per the Mermin–Wagner theorem. This shows that the amplitude of long-wavelength fluctuations grows logarithmically with the scale of a 2D structure, and would therefore be unbounded in structures of infinite size. Local deformation and elastic strain are negligibly affected by this long-range divergence in relative displacement. It is believed that a sufficiently large 2D structure, in the absence of applied lateral tension, will bend and crumple to form a fluctuating 3D structure. Researchers have observed ripples in suspended layers of graphene, and it has been proposed that the ripples are caused by thermal fluctuations in the material. As a consequence of these dynamical deformations, it is debatable whether graphene is truly a 2D structure. These ripples, when amplified by vacancy defects, induce a negative Poisson's ratio into graphene, resulting in the thinnest auxetic material known so far. Graphene-nickel (Ni) composites, created through plating processes, exhibit enhanced mechanical properties due to strong Ni-graphene interactions inhibiting dislocation sliding in the Ni matrix.
== External links == MedlinePlus Encyclopedia: C-reactive protein Inflammation, Heart Disease and Stroke: The Role of C-Reactive Protein (American Heart Association) C-Reactive+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CRP: analyte monograph - The Association for Clinical Biochemistry and Laboratory Medicine George Vrousgos, N.D. - Southern Cross University Archived 2020-02-18 at the Wayback Machine Human CRP genome location and CRP gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P02741 (C-reactive protein) at the PDBe-KB.
Carbon fibers are filaments of carbon that can be used to make very strong yarns and textiles. Carbon fiber items are often produced by spinning and weaving the desired item from fibers of a suitable polymer, and then pyrolyzing the material at a high temperature (from 1,500–3,000 °C or 2,730–5,430 °F). The first carbon fibers were made from rayon, but polyacrylonitrile has become the most common starting material. For their first workable electric lamps, Joseph Wilson Swan and Thomas Edison used carbon filaments made by pyrolysis of cotton yarns and bamboo splinters, respectively. Pyrolysis is the reaction used to coat a preformed substrate with a layer of pyrolytic carbon. This is typically done in a fluidized bed reactor heated to 1,000–2,000 °C or 1,830–3,630 °F. Pyrolytic carbon coatings are used in many applications, including artificial heart valves.
=== Environmental policy === Tetra Pak products have been identified as a solid waste problem by many NGOs and environmental groups. Unlike aluminum cans or glass bottles, it cannot be recycled in municipal recycling facilities. In order to stave off regulation, the company has engineered a strong Corporate Social Responsibility campaign. In 2011, Tetra Pak published a set of sustainability targets, which included maintaining its CO2 emission levels at the same level until 2020 and increasing recycling by 100 percent. Previous Tetra Pak sustainability targets (2005–2010) were met and exceeded. Maintaining current CO2 emission levels until 2020 would result in a 40 percent relative cut in emissions at an average growth rate of five percent per year, according to Food Production Daily. Tetra Pak said it will increase its use of Forest Stewardship Council (FSC) certified paper to 100 percent in 2020, with an interim target of 50 percent by 2012. The new targets will encompass the whole value chain, from suppliers to customers, putting pressure on partners to perform coherently. As of 2017, Tetra Pak was a Carbon Disclosure Project "A-lister" and 100% of its paperboard that year was either FSC-certified or came from other controlled sources that exclude "five environmentally and socially unacceptable categories as defined by the FSC." The company began producing paper straws for some of its smaller containers in 2019.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.